Two Major Drugs Pushed Back In One Day - The Return Of A Stricter US FDA?
COVID Vaccines and Alzheimer's Drug Will Be Next Tests
Knock-backs for Gilead/Galapagos and BioMarin are a surprise, and could be a sign of the FDA reasserting its 'gold standard' approach to safety and efficacy.
You may also be interested in...
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.